Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?

Effective treatment for heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine. The pathophysiological drivers of HFpEF are complex, differing depending on phenotype, making a one-size-fits-all treatment approach unlikely. Remarkably, sodium–glucose cotran...

Descripción completa

Detalles Bibliográficos
Autores principales: Deschaine, Brent, Verma, Sahil, Rayatzadeh, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2022
Materias:
Patients with HFpEF
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272408/
https://www.ncbi.nlm.nih.gov/pubmed/35846984
http://dx.doi.org/10.15420/cfr.2022.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272408/
https://www.ncbi.nlm.nih.gov/pubmed/35846984
http://dx.doi.org/10.15420/cfr.2022.11

Ejemplares similares